

U.S. Food and Drug Administration

Final Administrative Order (OTC000018)

Over-the-Counter Monograph M024: Anthelmintic Drug Products for Over-the-Counter Human Use (Posted December 16, 2021)

I. Summary

Over-the-Counter Monograph M024: Anthelmintic Drug Products for Over-the-Counter Human Use, as set forth in this document, is a final administrative order (final order) deemed by section 505G(b)(8) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355h(b)(8)), and effective upon enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law 116-136, on March 27, 2020.

II. Background

The CARES Act added section 505G of the FD&C Act, which revised the framework for the regulation of over-the-counter (OTC) monograph drug products. Among other things, section 505G of the FD&C Act provides as a baseline status that, as of the date of enactment of the CARES Act, drugs that satisfy certain requirements described in section 505G(a)(1) or (2) are deemed to be generally recognized as safe and effective under section 201(p)(1) of the FD&C Act (21 U.S.C. 321(p)(1)), not a new drug under section 201(p), and not subject to section 503(b)(1) of the FD&C Act (21 U.S.C. 353(b)(1)). To obtain this status, among other things, a drug either must be one that is in conformity with the requirements for nonprescription use of a final monograph issued under part 330 (21 CFR part 330) (except as provided in section 505G(a)(2)),¹ as well as other requirements,² or must be one that is (i) classified in category I for safety and effectiveness under a tentative final monograph that is the most recently applicable proposal or determination issued under part 330, and (ii) in conformity with the proposed requirements for nonprescription use of such tentative final monograph and any applicable subsequent determination by the Secretary, as well as other requirements.³ Other applicable requirements in section 505G(a)(1) of the FD&C Act include conditions or requirements under section 505G(b) of the FD&C Act.

Complementary to the requirements for conformity to tentative final or final monographs described in section 505G(a)(1) and (2) of the FD&C Act, Congress provided that, under section 505G(b)(8) of the FD&C Act, a final monograph or tentative final monograph that establishes

¹ Section 505G(a)(2) of the FD&C Act is inapplicable here. It establishes the applicable requirements in terms of conformity with a final monograph, for purposes of section 505G(a)(1)(A)(i) of the FD&C Act, for sunscreen drugs subject to section 505G of the FD&C Act.

² Section 505G(a)(1)(A) of the FD&C Act.

³ Section 505G(a)(1)(B) of the FD&C Act.

conditions of use for a drug described in section 505G(a)(1) or (2) and that represents the most recently promulgated version of the conditions of use, including as modified, in whole or in part, by any proposed or final rule, is deemed to be a final order. The final order may be amended, revoked, or otherwise modified in accordance with the procedures under section 505G of the FD&C Act. Under section 505G(b)(8)(C) of the FD&C Act, the deemed establishment of a final order is construed to include technical amendments necessary to ensure that the order is appropriately harmonized, in terms of terminology or cross-references, with the applicable provisions of the FD&C Act (and regulations) and any other final orders issued under section 505G of the FD&C Act.

In the *Federal Register* of August 1, 1986 (51 FR 27756 at 27759), FDA issued a final OTC monograph under the procedure in part 330, establishing conditions under which OTC anthelmintic drug products are generally recognized as safe and effective (GRASE). This final OTC monograph was codified in 21 CFR part 357, subpart B, and subsequently amended by final rules issued on September 5, 1986 (51 FR 31763), March 13, 1987 (52 FR 7830), and September 15, 1988 (53 FR 35808 at 35810).

Accordingly, this final order for OTC anthelmintic drug products incorporates the requirements of the final monograph for OTC anthelmintic drug products issued under part 330, as codified in part 357, subpart B as of March 27, 2020, with technical amendments, including consolidating professional use provisions into their own part.

III. Final Administrative Order

Over-the-Counter Monograph M024: Anthelmintic Drug Products for Over-the-Counter Human Use

Part A—General Provisions

Sec.

M024.1 Scope

M024.3 Definitions

Part B—Active Ingredients

M024.10 Anthelmintic active ingredient

Part C—Labeling

M024.50 Labeling of anthelmintic drug products

M024.52 Package inserts for anthelmintic drug products

Part D—Professional Use

§ M024.80 Professional labeling

SOURCE: 51 FR 27759, Aug. 1, 1986, unless otherwise noted.

Part A—General Provisions

§ M024.1 Scope

An over-the-counter (OTC) anthelmintic drug product in a form suitable for oral administration is generally recognized as safe and effective and is not misbranded if it meets each condition in this OTC monograph and each general condition established in 21 CFR 330.1.

§ M024.3 Definition

As used in this OTC monograph:

Anthelmintic. An agent that is destructive to worms.

Part B—Active Ingredients

§ M024.10 Anthelmintic active ingredient

The active ingredient of the product is pyrantel pamoate when used within the dosage limits established in § M024.50(d)(1).

Part C—Labeling

§ M024.50 Labeling of anthelmintic drug products

(a) Statement of identity. The labeling of the product contains the established name of the drug, if any, and identifies the product as a “pinworm treatment.”

(b) Indication. The labeling of the product states, under the heading “Use,” the following: “For the treatment of pinworms.” Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in § M024.50(b), may also be used, as provided in 21 CFR 330.1(c)(2), subject to the provisions of section 502 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 352) relating to misbranding and the prohibition in section 301(d) of the FD&C Act (21 U.S.C. 331(d)) against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the FD&C Act (21 U.S.C. 355(a)).

(c) Warnings. The labeling of the product contains the following warnings under the heading “Warnings”:

(1) “Abdominal cramps, nausea, vomiting, diarrhea, headache, or dizziness sometimes occur after taking this drug. If any of these conditions persist consult a doctor.”

(2) “If you are pregnant or have liver disease, do not take this product unless directed by a doctor.”

(d) Directions. The labeling of the product contains the following information under the heading “Directions”:

(1) Adults, children 12 years of age and over, and children 2 years to under 12 years of age: Oral dosage is a single dose of 5 milligrams of pyrantel base per pound, or 11 milligrams per kilogram, of body weight not to exceed 1 gram. Dosing information should be converted to easily understood directions for the consumer using the following dosage schedule:

Weight	Dosage (taken as a single dose) ¹
Less than 25 pounds or under 2 years old	Do not use unless directed by a doctor.
25 to 37 pounds	125 milligrams.
38 to 62 pounds	250 milligrams.
63 to 87 pounds	375 milligrams.
88 to 112 pounds	500 milligrams.
113 to 137 pounds	625 milligrams.
138 to 162 pounds	750 milligrams.
163 to 187 pounds	875 milligrams.
188 pounds and over	1,000 milligrams.

¹Depending on the product, the label should state the quantity of drug as a liquid measurement (e.g., teaspoonsful) or as the number of dosage units (e.g., tablets) to be taken for the varying body weights. (If appropriate, it is recommended that a measuring cup graduated by body weight and/or liquid measurement be provided with the product.) Manufacturers should present this information as appropriate for their product and may vary the format of this chart as necessary.

(2) “Read package insert carefully before taking this medication. Take only according to directions and do not exceed the recommended dosage unless directed by a doctor. Medication should only be taken one time as a single dose; do not repeat treatment unless directed by a doctor. When one individual in a household has pinworms, the entire household should be treated unless otherwise advised. See Warnings. If any worms other than pinworms are present before or after treatment, consult a doctor. If any symptoms or pinworms are still present after treatment, consult a doctor.

(3) “This product can be taken any time of day, with or without meals. It may be taken alone or with milk or fruit juice. Use of a laxative is not necessary prior to, during, or after medication.”

(e) Optional wording. The word “physician” may be substituted for the word “doctor” in any of the labeling statements in § M024.50.

[51 FR 27759, Aug. 1, 1986; 52 FR 7831, Mar. 13, 1987, as amended at 53 FR 35810, Sept. 15, 1988]

§ M024.52 Package inserts for anthelmintic drug products

The labeling of the product contains a consumer package insert that includes the following information:

- (a) A discussion of the symptoms suggestive of pinworm infestation, including a statement that pinworms must be visually identified before taking this medication.
- (b) A detailed description of how to find and identify the pinworm.
- (c) A commentary on the life cycle of the pinworm.
- (d) A commentary on the ways in which pinworms may be spread from person to person and hygienic procedures to follow to avoid such spreading.
- (e) The appropriate labeling information contained in § M024.50.

[51 FR 27759, Aug. 1, 1986, as amended at 52 FR 2515, Jan. 23, 1987]

Part D—Professional Use

§ M024.80 Professional labeling

The labeling provided to health professionals (but not to the general public) may contain an additional indication: “For the treatment of common roundworm infestation.”